Tech Company Financing Transactions

Antiva Biosciences Funding Round

Antiva Biosciences closed a $22 million Series C financing round on 3/29/2017. Backers included Brace Pharma, Alexandria Venture Investments and Canaan Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

14024 Rue Saint Raphael
Del Mar, CA 92014
USA

Phone

Undisclosed

Website

Email Address

Not Recorded

Overview

Antiva Biosciences was founded by Karl Hostetler, M.D., a leader in virology who founded Chimerix, Triangle Therapeutics (acquired by Gilead) and Vical. The company is using a new medicinal chemistry platform to develop antiviral therapies, focusing first on HPV. Antiva has additional molecules that target HIV, the herpes virus, cytomegalovirus and others.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Founder

Karl Hostetler

        

Browse more venture capital transactions:

Prev: 3/29/2017: Vascular Dynamics venture capital transaction
Next: 3/29/2017: Rigetti Computing venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary